Bicycle Therapeutics (NASDAQ:BCYC) Shares Down 3.8%

Shares of Bicycle Therapeutics plc (NASDAQ:BCYC - Get Free Report) were down 3.8% during mid-day trading on Monday . The company traded as low as $23.46 and last traded at $23.64. Approximately 121,193 shares traded hands during mid-day trading, a decline of 67% from the average daily volume of 370,754 shares. The stock had previously closed at $24.58.

Wall Street Analyst Weigh In

A number of equities research analysts have issued reports on BCYC shares. Needham & Company LLC reiterated a "buy" rating and issued a $43.00 target price on shares of Bicycle Therapeutics in a research report on Wednesday, April 10th. Canaccord Genuity Group restated a "buy" rating and set a $60.00 price target on shares of Bicycle Therapeutics in a research note on Wednesday, February 21st. Finally, HC Wainwright restated a "buy" rating and set a $55.00 price target on shares of Bicycle Therapeutics in a research note on Friday. One equities research analyst has rated the stock with a hold rating and six have assigned a buy rating to the stock. Based on data from MarketBeat, the company presently has an average rating of "Moderate Buy" and an average target price of $46.86.

Bicycle Therapeutics Stock Performance

The firm has a 50 day moving average price of $24.02 and a two-hundred day moving average price of $19.49. The company has a quick ratio of 10.42, a current ratio of 10.42 and a debt-to-equity ratio of 0.09.

Bicycle Therapeutics (NASDAQ:BCYC - Get Free Report) last released its quarterly earnings results on Thursday, May 2nd. The company reported ($0.62) EPS for the quarter, topping analysts' consensus estimates of ($1.25) by $0.63. The business had revenue of $19.53 million for the quarter, compared to analyst estimates of $6.06 million. Bicycle Therapeutics had a negative return on equity of 49.35% and a negative net margin of 404.14%. Bicycle Therapeutics's revenue for the quarter was up 298.9% on a year-over-year basis. Analysts forecast that Bicycle Therapeutics plc will post -5.13 earnings per share for the current year.

Insider Buying and Selling at Bicycle Therapeutics

In other Bicycle Therapeutics news, CEO Kevin Lee sold 3,158 shares of the company's stock in a transaction that occurred on Wednesday, April 3rd. The shares were sold at an average price of $23.81, for a total value of $75,191.98. Following the completion of the sale, the chief executive officer now owns 387,270 shares of the company's stock, valued at $9,220,898.70. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In the last three months, insiders have sold 5,312 shares of company stock worth $126,139. Company insiders own 8.50% of the company's stock.

Institutional Investors Weigh In On Bicycle Therapeutics

Several institutional investors have recently added to or reduced their stakes in the stock. BluePath Capital Management LLC bought a new stake in Bicycle Therapeutics during the 3rd quarter worth about $31,000. China Universal Asset Management Co. Ltd. increased its stake in shares of Bicycle Therapeutics by 489.2% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 4,001 shares of the company's stock worth $72,000 after purchasing an additional 3,322 shares during the last quarter. Exchange Traded Concepts LLC increased its stake in shares of Bicycle Therapeutics by 34.0% during the 4th quarter. Exchange Traded Concepts LLC now owns 6,727 shares of the company's stock worth $122,000 after purchasing an additional 1,706 shares during the last quarter. PNC Financial Services Group Inc. acquired a new position in shares of Bicycle Therapeutics during the 4th quarter worth about $137,000. Finally, PDS Planning Inc acquired a new position in shares of Bicycle Therapeutics during the 1st quarter worth about $210,000. 86.15% of the stock is owned by institutional investors.

Bicycle Therapeutics Company Profile

Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics in the United States and the United Kingdom. Its product pipeline comprising BT8009, a bicycle toxin conjugate (BTC) which is in phase I/II/III clinical trial for the treatment of high nectin-4 expressing tumors; BT5528, a BTC which is in phase I/II clinical trial for the treatment of Ephrin type A receptor 2 expressing tumor; BT7480, a Bicycle TICA molecule which is in phase I/II targeting Nectin-4 and agonizing CD137; and BT7455, a Bicycle TICA molecule targeting Ephrin type A receptor 2 and CD137 and is in preclinical trial.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.